Cost-Effectiveness of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Hematopoietic Stem Cell Transplant Recipients and Other Immunocompromised Adults in the United States.

Ahmed Ehab Salem Elizabeth M La Desmond Curran Brandon J Patterson Justin Carrico Stéphane Lorenc Katherine A Hicks Sara Poston Christopher F Carpenter

Published in: PharmacoEconomics - open (2023)

Model results show RZV is potentially cost saving for the prevention of HZ in US adult HSCT recipients and US adults with selected immunocompromising conditions, and cost effective for others, supporting the use of RZV to prevent HZ and HZ-related complications in IC adults.

Keyphrases

hematopoietic stem cell
risk factors
intensive care unit
cell free
young adults
kidney transplantation
mechanical ventilation
drug induced